CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) – Cyclerion Therapeutics, Inc. (CYCN) today announced that company management will present an overview of the company at the Jefferies Virtual Healthcare conference on Tuesday, 1 June 2021 at 4:00 p.m. pm ET. Management will also be available for one-on-one meetings and investors can request a meeting through Jefferies.
The live webcast can be accessed through the Investors & Media section of Cyclerion’s website at https://ir.cyclerion.com/news-events/event-calendar. An archived replay of the event will be available on the site for approximately 90 days after the presentation.
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company whose mission is to develop treatments that restore cognitive function. CyclerionÃ¢ ???? advances novel, first-class, CNS-penetrating sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by stimulation of sGC has the potential to impact a wide range of CNS diseases. The most advanced compound, CY6463, has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer’s disease with vascular disease (vAD) and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes. (MELAS) and cognitive disorders associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next-generation sGC stimulator.
Carlo Tanzi, Ph.D.
Kendall Investor Relations
Scientific communications from Verge